Are you Dr. Levis?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 69 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
401 North Broadway Street
Weinberg BLDG
Baltimore, MD 21287
Summary
- Dr. Mark Levis, MD is an oncologist in Baltimore, Maryland. He is currently licensed to practice medicine in Maryland and District of Columbia. He is affiliated with Johns Hopkins Hospital and Sibley Memorial Hospital.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1999 - 2002- Johns Hopkins UniversityResidency, Internal Medicine, 1994 - 1997
University of California San Francisco School of MedicineClass of 1994
Certifications & Licensure
DC State Medical License 2017 - 2026
MD State Medical License 1997 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2011 Nov 21
- Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 02
Publications & Presentations
PubMed
- Reply to S. Fuji.Mark J Levis, Mehdi Hamadani, Mary M Horowitz, Yi-Bin Chen,
Journal of Clinical Oncology. 2024-11-10 - Targeting rapid TKI-induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia.Tessa S Seale, Li Li, J Kyle Bruner, Melody Chou, Bao Nguyen
Molecular Oncology. 2024-10-12 - Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.Betty K Hamilton, Bhavik J Pandya, Cristina Ivanescu, Dina Elsouda, Mehdi Hamadani
Blood Advances. 2024-10-08
Press Mentions
Improving Risk Stratification in Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia in ChildrenApril 21st, 2023- AML Research from ASH 2022: Novel Combinations and Evidence That “Less Is More”February 8th, 2023
- The Efficacy of ATO and ATRA for APLOctober 13th, 2021
- Join now to see all
